As scientific knowledge advances and regulatory guidelines evolve, with Karuna, 2024 was the year where the mental health treatment landscape changed thanks to the innovative development of brand new, next-generation neuropsychiatric drugs.
More than 100 industry leaders attended the 7th Neuropsychiatric Drug Development conference in September 2024, to transform knowledge, share cutting-edge advancements and foster pre-competitive collaboration to innovate precision psychiatry, propel next-generation drug R&D and fuel more clinical approvals
Attendees Had the Opportunity To:
Hear from 30+ brand-new speakers from the likes of Janssen, Biogen, Sumitomo Pharma America, AbbVie, Lykos Therapeutics, Boehringer Ingelheim and Compass Pathways
Broaden your knowledge with specialized case studies covering PTSD, Behavioural Symptoms Associated with FTD, Substance Use Disorders, Bipolar and many more
Engage in 12+ hours of interactive workshop discussions spanning translational EEGs, behavioural and circuit-based in vivo models, efficacy of hallucinogens, and placebo-mitigating trial designs with Sage Therapeutics, Otsuka, Lundbeck, Gilgamesh, Delix and more
Participate in either the ‘Discovery & Preclinical’ or ‘Translational & Clinical’ track of the main conference days to ensure your time out of the office is completely relevant
Discover new next-generation targets, modalities, and technologies from 8+ new presenting companies including Karuna, Click, MapLight and Sensorium Therapeutics
Who Would You Have Met?
Access the Comprehensive Event Guide With 35+ Speakers, 2 Tracks of Content, 4 Pre-conference Workshops & More!
